A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Phase 1/2 Recruiting
231 enrolled
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Phase 2/3 Recruiting
806 enrolled
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 Recruiting
134 enrolled
SYNERGY-101
Phase 1/2 Recruiting
364 enrolled
CEMI-LUNG
Recruiting
500 enrolled
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Phase 3 Recruiting
416 enrolled
PROSPER
Phase 1/2 Recruiting
403 enrolled
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Phase 1 Recruiting
514 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
BA-004
Phase NA Recruiting
2,063 enrolled
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Phase 3 Recruiting
400 enrolled
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
386 enrolled
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 Recruiting
144 enrolled
DART-NK-SCLC
Phase 1/2 Recruiting
60 enrolled
VELOCITY-Lung
Phase 2 Recruiting
270 enrolled
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
416 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
370 enrolled
ADVICE
Phase 1/2 Recruiting
80 enrolled
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Recruiting
105 enrolled
MountainTAP-29
Phase 2/3 Recruiting
590 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
SEZanne
Phase 2 Recruiting
180 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
MK-3475-01A
Phase 1/2 Recruiting
450 enrolled
MK-3475-U01
Recruiting
1,065 enrolled
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
698 enrolled
ORI-EGI-03
Recruiting
450 enrolled
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 Recruiting
710 enrolled
KANDLELIT-004
Phase 3 Recruiting
600 enrolled
TROPION-Lung10
Phase 3 Recruiting
675 enrolled
CONVERGE
Phase 2 Recruiting
130 enrolled
MK-6070-002
Phase 1/2 Recruiting
262 enrolled
KANDLELIT-007
Phase 3 Recruiting
675 enrolled
MK-3475-01F
Phase 1/2 Recruiting
190 enrolled
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/2 Recruiting
428 enrolled
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Phase 1 Recruiting
453 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Phase 1 Recruiting
126 enrolled
COCOON
Phase 2 Recruiting
300 enrolled
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1 Recruiting
914 enrolled
TroFuse-007
Phase 3 Recruiting
614 enrolled
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1/2 Recruiting
342 enrolled
MK-2870-009
Phase 3 Recruiting
520 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Phase 3 Recruiting
851 enrolled
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Phase 2 Recruiting
60 enrolled
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Phase 3 Recruiting
630 enrolled
DLLEVATE
Phase 3 Recruiting
480 enrolled